General Information of Drug (ID: DMBA4DK)

Drug Name
APC-6336 Drug Info
Synonyms CRA-6336; HCV therapy, BMS/Arris; HCV therapy, BMS/Axys; Hepatitis C therapy, Axys/BMS; Protease inhibitors, BMS/Arris; Protease inhibitors, BMS/Axys
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Terminated [1]
Cross-matching ID
PubChem CID
72941786
CAS Number
CAS 263870-19-5
TTD Drug ID
DMBA4DK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Enzyme unspecific (Enz)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [3]
Desoxyribonuclease DMEZFXR Female genital tract inflammation GA0Z Approved [4]
VT-1129 DMCGK9H Onchocerciasis 1F6A Phase 2 [5]
HTI-101 DMURXMJ Obesity 5B81 Phase 2 [6]
ASC-101 DMVNCSK Haematological malignancy 2B33.Y Phase 1/2 [7]
BXCL702 DMY9L4C Haematological malignancy 2B33.Y Phase 1 [8]
NZ-1002 DMINSRW Lysosomal storage disease 5C56.Z Terminated [9]
A-11259 DMZ5NQP Bacterial infection 1A00-1C4Z Terminated [10]
SRI-3072 DMBEUN6 Mycobacterium infection 1B10-1B21 Terminated [11]
GW-278884 DMUG82P Colorectal cancer 2B91.Z Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Enzyme unspecific (Enz) TT3C1VN NOUNIPROTAC Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010742)
2 CN patent application no. 103263414, Application of 2,2'-(1,4-phenylene)di(benzimidazole-5-carboxylic acid) in preparation of antitumor drug.
3 Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41.
4 Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52.
5 The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7.
6 Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006.
7 ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Expression of a cytokinin synthesis gene from Agrobacterium tumefaciens T-DNA in basket willow (Salix viminalis). Physiologia Plantarum Volume 88, Issue 3, pages 439-445, July 1993.
10 The Identification of Nanomolar 1,4-benzoquinone Inhibitors of Shikimate Kinase. Aspergillus & Aspergillosis Website. 2002.
11 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother. 2002 Jul;50(1):111-4.
12 WO patent application no. 2010,1112,71, Orally bioavailable lipid-based constructs.